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Abstract We previously found that retinoblastoma (RB) is 
cleaved at the initiation of apoptotic execution. Here we report 
that when an HL-60 cell line resistant to cytosine arabinoside 
(Ara-C) was exposed to this anticancer drug, neither RB 
cleavage nor apoptosis was detected. Consistent with that, 
processing of interleukin lP_converting enzyme (ICE) and 
CPP32 (an ICE&e protease) was also prevented in these cells. 
In contrast, treatment of the HL-60-Ara-C-resistant cells with 
etoposide induced all of these apoptotic events. Furthermore, the 
etoposide-induced RB cleavage was inhibited by a specific 
tetrapeptide ICE-like inhibitor. Our results demonstrate that 
activation of the RB cleavage enzyme, an ICE-like protease, is 
required for overcoming drug resistance. 
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1. Introduction 
Despite the achievements in the design and use of chem- 
otherapeutic agents, the majority of human cancers at present 
are resistant to therapy [l-3]. It has been suggested that pro- 
teins mediating cancer cell sensitivity to chemotherapy may 
also play a role in regulating processes of proliferation and 
apoptosis (or programmed cell death) [l-3]. For example, 
resistance to anticancer drugs and radiation is associated 
with inactivation of the tumor suppressor protein p53 [1,2], 
or overexpression of Bcl-2 oncoprotein [1,3]. 
Apoptosis is an active process of cell death, which occurs in 
two physiological stages, commitment and execution [4]. Little 
is known about molecular controls of the apoptotic commit- 
ment in mammalian cells. It has been proposed that induction 
of ~53 might be sufficient to commit cells to undergo apop- 
tosis [5], whereas overexpression of Bcl-2 oncoprotein can 
block this process [6]. Apoptotic execution in mammalian cells 
is initiated by specific proteases of the interleukin lp-convert- 
ing enzyme (ICE) family [4]. The active ICE enzyme consists 
of two subunits, p20 and ~10, processed from a 45 kDa pre- 
cursor [7]. CPP32 is another member of the ICE family [8]. 
The full-length 32 kDa form of CPP32 (pro-CPP32) repre- 
sents an inactive zymogen. Upon stimulation of apoptosis, 
pro-CPP32 is processed to its active form, p20 and pll sub- 
units [8,9]. It has also been found that at the initiation of 
apoptotic execution, the activated CPP32 cleaves poly(ADP- 
ribose) polymerase (PARP) [9]. The importance of PARP 
cleavage to the death process remains unknown. 
We previously found that when human leukemia cells were 
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treated with a variety of anticancer agents, retinoblastoma 
(RB) became dephosphorylated [lo], and then immediately 
cleaved [1 11. Two major cleavage fragments of RB, p48 and 
~68, were detected by monoclonal RB antibodies G3-245 
(which recognizes an epitope between amino acids 300 and 
380 [12]) and Xi% (which recognizes epitopes between 444 
and 621 and between 646 and 665 [13]), respectively. Here, we 
report that HL-60 cells resistant to cytosine arabinoside (HL- 
60-Ara-C-resistant cells [14]), when exposed to Ara-C, failed 
to cleave RB, did not activate ICE and CPP32, and did not 
induce apoptosis. However, treatment of the Ara-C-resistant 
cells with etoposide (VP-16), another anticancer agent that 
acts through a different mechanism, induced all of these apop- 
totic events. Furthermore, the VP-16-induced RB cleavage in 
these cells was blocked by a specific tetrapeptide inhibitor of 
ICE-like proteases. 
2. Materials and methods 
2.1. Materials 
Mouse monoclonal culture supernatant to human RB, XZ55, was a 
kind gift from Drs. N. Dyson and E. Harlow (Massachusetts General 
Hospital Cancer Center, Charlestown, MA). Purified mouse monoclo- 
nal antibody to human RB, G3-245, was purchased from PharMin- 
gen; purified rabbit polyclonal antibody to p20 subunit of human ICE 
from-Upstate Biotechnology Inc.; purified mouse monoclonal anti- 
bodv to ~20 subunit of human CPP32 from Transduction Labora- 
tories. The specific tetrapeptide ICE-like inhibitor, acetyl-YVAD- 
chloromethyl ketone (WAD-CMK), was from Bachem. VP-16, 
Ara-C and other chemicals were from Sigma. 
2.2. Cell culture 
HL-60-Ara-C-resistant cell line was a gift originally from Dr. K. 
Bhalla (Medical University of South Carolina). Both HL-60 and HL- 
60-Ara-C-resistant cells were grown in RPM1 1640 (Life Technologies, 
Inc.) supplemented with 10% fetal calf serum (Sigma), 100 unit/ml of 
penicillin, 100 pg/ml of streptomycin and 2 mM L-glutamine. 
2.3. Whole cell extracts and Western blot assay 
Whole cell extraction [ll] and the enhanced chemiluminescence 
Western blot assay [15] were performed as described previously. 
3. Results 
3.1. Failure to cleave RB in HL-60-Ara-C-resistant cells 
We had found that when HL-60 cells were exposed to Ara- 
C or VP-16, RB was first dephosphorylated and then imme- 
diately cleaved. This RB cleavage was accompanied by the 
internucleosomal fragmentation of DNA (a 180 base-pair 
DNA ladder) [ll]. We speculated that if RB cleavage is crit- 
ical for the initiation of apoptotic execution, failure to cleave 
RB should be associated with drug resistance. In this study, 
we used a pair of HL-60 cell lines that were sensitive [lo] or 
resistant [14] to the anticancer drug Ara-C. Both HL-60 and 
HL-60-Ara-C-resistant cells were treated with Ara-C, followed 
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Fig. 1. Failure to cleave RB in HL-60-Ara-C-resistant cells. Both 
HL-60 (S) and HL-60-Ara-C-resistant (R) cells were treated with 10 
uM Ara-C (+) or an equal percentage (0.02%) of PBS (-) for 4 h, 
followed by preparation of whole cell extracts and Western blot 
analysis using a purified monoclonal antibody to human RB, G3- 
245. Bands of RB and its cleavage fragment, ~48, are indicated. 
by the measurement of RB cleavage (by Western blot assay) 
and apoptosis (by DNA fragmentation assay). 
When HL-60 cells were exposed to Ara-C for 4 h, an abun- 
dant band with molecular mass 48 kDa (~48) was detected by 
purified monoclonal RB antibody G3-245 (Fig. 1, lane 2) 
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suggesting RB cleavage. At the same time, a 180 base-pair 
DNA ladder was detected [lo]. The p48 fragment of RB 
was not found in HL-60 cells that had been treated with the 
drug-vehicle, PBS (Fig. 1, lane l), demonstrating that RB 
cleavage is Ara-C-induced. 
In contrast, When HL-60-Ara-C-resistant cells were treated 
with Ara-C for 4 h, neither the ~48 fragment of RB (Fig. 1, 
lane 4) nor DNA fragmentation [16] was detected. Therefore, 
failure to cleave RB is associated with failure to induce apop- 
tosis in these cells. 
3.2. VP-16 induces RB cleavage in HL-60-Ara-C-resistant 
cells, which is inhibitable by YVAD-CMK 
We had found that HL-60-Ara-C-resistant cells were sensi- 
tive to treatment of VP-16 (see Fig. 2) another anticancer 
agent that acts via a different mechanism (as an inhibitor of 
topoisomerase II [17]). We investigated whether exposure to 
VP-16 of HL-60-Ara-C-resistant cells induced RB cleavage. 
When the Ara-C-resistant cells were treated with VP-16 for 
34 h, RB was converted from the hyperphosphorylated 
(pl20/hyper) to a hypophosphorylated form (pl lS/hypo) 
(Fig. 2, lanes 9,lO vs. lanes 7,s). Furthermore, after 4 h VP- 
16 treatment, bands of 68 kDa (~68) were detected by the 
monoclonal RB antibody XZ55 (Fig. 2, lane 10). The level 
of the p68 fragment of RB was increased afterwards (Fig. 2, 
lane 11). The p48 fragment of RB was also generated accord- 
ing to similar kinetics, detected by the monoclonal RB anti- 
body G3-245 (data not shown). These data demonstrate that 
VP-16 induces the process of RB cleavage in HL-60-Ara-C- 
resistant cells. 
Associated with cleavage of RB, internucleosomal DNA 
fragmentation was detected in the VP-16-treated Ara-C-resist- 
ant cells [16]. Neither RB cleavage nor DNA fragmentation 
was found in HL-60-Ara-C-resistant cells treated with di- 
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Fig. 2. Induction of RB cleavage by VP-16 in HL-60-Ara-C-resistant cells. Both HL-60 (Sensitive) and HL-60-Ara-C-resistant (Resistant) cells 
were treated with 20 pM VP-16 or an equal percentage (0.01%) of dimethyl sulfoxide (D) for the indicated hours. Western blot assay was per- 
formed using a mouse monoclonal culture supernatant to human RB, XZ55. The hyperphosphorylated form (pl20/hyper), hypophosphorylated 
form (pll5/hypo) and a cleavage fragment (~68) of RB are indicated. 
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Fig. 3. Inhibition of the VP-16-induced RB cleavage by WAD-CMK in HL-60-Ara-C-resistant cells. Ara-C-resistant cells were treated with 10 
uM VP-16 (+VP-16) for 1 h and then incubated in drug-free medium (-VP-16) for an additional 6 h in the absence (-) or presence of various 
concentrations of WAD-CMK as indicated. Western blot assay was performed using RB antibody XZ55. The pl20/hyper, pl1Yhypo and the 
~68 fragment of RB are indicated. 
methyl sulfoxide, the solvent of VP-16 (Fig. 2, lane 12). These 
data strongly suggest that induction of RB cleavage is corre- 
lated with overcoming drug resistance in these cells. 
As a control, treatment of normal HL-60 cells with VP-16 
for 4-5 h also induced RB dephosphorylation and cleavage 
(Fig. 2, lanes 4, 5). The VP-16-induced RB changes occurred 
earlier in HL-60-Ara-C-resistant cells than in HL-60 cells (Fig. 
2), indicating that HL-60-Ara-C-resistant cells are more sen- 
sitive to treatment with VP-16. These results also indicate that 
pathways for induction of RB cleavage are intact in the Ara- 
C-resistant cells. 
To investigate whether VP-16 activates an ICE-like protease 
that mediates RB cleavage in HL-60-Ara-C-resistant cells, we 
used YVAD-CMK, a well-characterized specific tetrapeptide 
inhibitor of ICE-like proteases [7]. The Ara-C-resistant cells 
were pretreated with VP-16 for 1 h, washed and then incu- 
bated in drug-free medium for an additional 6 h. Using this 
procedure we found that transient exposure to VP-16 for 1 h 
was sufficient to generate readily detectable p68 fragment of 
RB (Fig. 3, lane 2 vs. lane 1). Addition of WAD-CMK at the 
start of the 6 h incubation effectively blocked production of 
the p68 fragment: 50% at 50 nM, 80% at 10 pM and 100% at 
50 pM (Fig. 3, lanes 3-6 vs. lane 2). Inhibition of RB cleavage 
by WAD-CMK was accompanied by an increase in the level 
of pllS/hypo/RB (Fig. 3, lane 6 vs. 2), supporting the idea 
that pl 1 S/hypo/RB is the substrate of the RB cleavage en- 
zyme. In contrast, addition of tosyl-L-lysine chloromethyl ke- 
tone, a non-specific ketone protease inhibitor, at 50 pM had 
no effect (data not shown). These data indicate that a VP-16- 
induced ICE-like protease mediates the process of RB cleav- 
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Fig. 4. Failure to activate ICE and CPP32 in HL-60-Ara-C-resistant cells. Both HL-60 (Sensitive) and HL-60-Ara-C-resistant (Resistant) cells 
were treated with 10 uM Ara-C or an equal percentage (0.02%) of PBS (P) for the indicated hours, followed by preparation of whole cell ex- 
tracts. Western blot analysis was performed by using purified antibodies to p20 subunit of human ICE (a), or p20 subunit of human CPP32 
(b). Bands of p20/ICE, p2O/CPP32 and the full length of CPP32 (ProCPP32) are indicated. 
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Fig. 5. Activation of ICE and CPP32 by VP-16 in HL-60-Ara-C-resistant cells. Both HL-60 (Sensitive) and HL-60-Ara-C-resistant (Resistant) 
cells were treated with 20 ,uM VP-16 or an equal percentage (0.01%) of dimethyl sulfoxide (D) for the indicated hours. Western blot assay was 
performed by using purified antibodies to p20/ICE (a) or p2O/CPP32 (b). Bands of p20/ICE, p2O/CPP32 and the full length of CPP32 (Pro- 
cPP32) are indicated: 
age in HL-60-Ara-C-resistant cells. Activation of the ICE-like 
protease and consequent RB cleavage is, therefore, associated 
with overcoming drug resistance. 
3.3. VP-16 but not Ara-C activates ice and CPP32 in 
HL-60-Ara-C-resistant cells 
Because cleavage of RB is mediated by an ICE-like protease 
activity (Fig. 3) failure to cleave RB in HL-60-Ara-C-resist- 
ant cells (Fig. 1) might be due to inhibition of the ICE-like 
protease activation. To test this hypothesis, we treated both 
HL-60 and HL-60-Ara-C-resistant cells with Ara-C for up to 
5 h, and measured levels of p20/ICE and p2O/CPP32, the 
active forms of these enzymes [7,9], by using their specific 
monoclonal antibodies. When HL-60 cells were exposed to 
Ara-C for 3 h, a faint band of 20 kDa (p20/ICE) was detected 
by its specific antibody (Fig. 4a, lane 3). The level of p20/ICE 
was further increased afterwards (Fig. 4a, lanes 4,5). The level 
of p2O/CPP32 was increased after 45 h treatment with Ara-C 
(Fig. 4b, lanes 4,5), detected by a purified antibody to the p20 
subunit of CPP32. Neither p201ICE nor p2OlCPP32 was found 
in the control-treated HL-60 cells (Fig. 4a,b, lane 6). The 
observation that processing of ICE preceded that of CPP32 
(Fig. 4a vs. b) is consistent with the idea that activated ICE 
cleaves and activates CPP32 during cellular apoptosis [18]. 
The kinetics of ICE/CPP32 processing is comparable to that 
of RB cleavage (Fig. 4 vs. Fig. 1 and [ll]), supporting the 
hypothesis that an ICE-like protease cleaves RB. 
In contrast, when HL-60-Ara-C-resistant cells were exposed 
to Ara-C for up to 5 h, neither p20/ICE nor p2O/CPP32 was 
observed (Fig. 4a,b, lanes 7-12). Therefore, inhibition of ICE/ 
CPP32 activation is associated with failure to cleave RB in 
these Ara-C-resistant cells (Figs. 1 and 4). 
We predicted that treatment of HL-60-Ara-C-resistant cells 
with VP-16 would activate ICE and CPP32. Indeed, when 
these Ara-C-resistant cells were treated with VP-16 for 3-5 
h, p20/ICE became detectable (Fig. 5a, lanes 9-11). At the 
same time, CPP32 was also activated because the level of 
pro-CPP32 was decreased and a faint band of p2O/CPP32 
was observed (Fig. 5b, lanes 9-11). The kinetics of ICE/ 
CPP32 activation is correlated well with that of RB cleavage 
in HL-60-Ara-C-resistant cells treated with VP-16 (compare 
Fig. 5 to Fig. 2). These results further support the hypothesis 
that VP-16 activates an ICE-like protease that cleave RB in 
the Ara-C-resistant cells. 
When normal HL-60 cells were treated with VP-16 for up 
to 5 h, pZO/ICE also became detectable (Fig. 5a, lanes l-6). 
CPP32 also became activated in these cells, as demonstrated 
by a decreased level of pro-CPP32 and the appearance of a 
faint p2O/CPP32 band (Fig. 5b, lanes l-6). Taken together, 
these results demonstrate that signal transduction pathways 
for ICE/CPP32 activation are intact in the Ara-C-resistant 
cells. 
4. Discussion 
We found that when normal HL-60 cells were induced to 
undergo apoptosis by Ara-C, RB cleavage occurred (Fig. l), 
accompanied by processing and activation of ICE and CPP32 
(Fig. 4). In contrast, HL-60-Ara-C-resistant cells, when ex- 
posed to Ara-C, failed to induce these events and apoptosis 
(Figs. 1 and 4). However, treatment of HL-60-Ara-C-resistant 
cells with VP-16 induced RB cleavage, ICE/CPP32 activation 
and apoptosis (Figs. 2 and 5). Furthermore, the VP-16-m 
duced RB cleavage in the Ara-C-resistant cells was blocked 
by a specific ICE-like protease inhibitor, YVAD-CMK 
(Fig. 3). 
Although both Ara-C and VP-16 are DNA-damaging 
agents, they act through different mechanisms. It has been 
suggested that cellular deoxycytidine kinase activates Ara-C, 
which inhibits DNA polymerase [19]. In addition, incorpora- 
tion of Ara-C into cellular DNA results in premature chain 
termination which may also count for the Ara-C-mediated 
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cytotoxicity [20]. In contrast, VP-16 inhibits the catalytic ac- 
tivity of topoisomerase II [17]. More importantly, this inhibi- 
tion leads to stabilization of the normally transient covalent 
intermediate formed between the DNA substrate and the en- 
zyme [17]. It has been reported that the HL-60-Ara-C resist- 
ant cells used in our studies had a low level of deoxycytidine 
kinase and decreased ability to transport Ara-C [14]. There- 
fore, these resistant cells are unable to efficiently activate Ara- 
C and/or incorporate Ara-C into DNA, resulting in insuffi- 
cient DNA damage. This is probably responsible for the fail- 
ure to cleave RB, to activate ICEICPP32 and to induce apop- 
tosis in HL-60-Ara-C-resistant cells (Figs. 1 and 4). Because 
these cells also failed to dephosphorylate RB (Fig. 1 and [16]), 
failure to cleave RB in these cells, therefore, may be due to 
inhibition of both the substrate production and protease acti- 
vation. 
In contrast to Ara-C, VP-16 effectively induced RB cleav- 
age, ICEICPP32 activation and apoptosis in the Ara-C-resist- 
ant cells (Figs. 2 and 5). Because pretreatment of these cells 
with VP-16 for 1 h was sufficient to induce these events (Fig. 
3) VP-16 must be able to generate sufficient DNA damage in 
these cells for induction of these apoptotic events. 
The concept of apoptosis inhibition could be of great im- 
portance since the consequence of apoptosis inhibition is the 
resistance of cancer cells to chemotherapy. Abolishment of 
apoptosis inhibition, therefore, could be a novel strategy for 
treatment of drug-resistant cancers. With further understand- 
ing of the molecular mechanisms of apoptosis it may even- 
tually be possible to develop novel cancer therapies that spe- 
cifically seek to modulate the physiologic cell death pathway. 
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